Table 3.
Expression of TIM3-related molecules in post-anti-PD-1 therapy samples.
| Case | Regimen of IO therapy | BOR | Area of tumor tissues | IHC findings |
||
|---|---|---|---|---|---|---|
| TIM3 expression | HMGB1 localization | Accumulation of CD163 macrophages | ||||
| Case 1 | Nivo | CR | Necrotic area | + | Ex | + |
| Case 2 | Nivo | SD | Necrotic area | + | Ex | + |
| Viable area | + | N | – | |||
| Case 3 | Nivo | PD | Viable area | – | N | – |
| Case 4 | Nivo+Ipi | PR | Necrotic area | + | Ex | + |
| Viable area | + | N | – | |||
| Case 5 | Nivo+Ipi | PR | Necrotic area | + | Ex | + |
| Viable area | + | N | – | |||
IO; immune-oncology, IHC; immunohistochemistry, BOR; best overall response.
Nivo; Nivo monotherapy, Nivo+Ipi; Nivo+Ipi therapy, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease, Ex; extra-nuclear region, N; nucleus.